These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 33995605)

  • 41. Inappropriate dosing of direct oral anticoagulants in patients with atrial fibrillation.
    Lavoie K; Turgeon MH; Brais C; Larochelle J; Blais L; Farand P; Letemplier G; Perreault S; Beauchesne MF
    J Atr Fibrillation; 2016 Dec; 9(4):1478. PubMed ID: 29250254
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation.
    Shah S; Norby FL; Datta YH; Lutsey PL; MacLehose RF; Chen LY; Alonso A
    Blood Adv; 2018 Feb; 2(3):200-209. PubMed ID: 29378726
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
    Andersson NW; Svanström H; Lund M; Pasternak B; Melbye M
    Int J Cardiol; 2018 Oct; 268():113-119. PubMed ID: 29934230
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Concurrent use of statins decreases major bleeding and intracerebral hemorrhage in non-valvular atrial fibrillation patients taking direct oral anticoagulants-A nationwide cohort study.
    Wu HH; Chang SH; Lee TH; Tu HT; Liu CH; Chang TY
    Front Cardiovasc Med; 2022; 9():969259. PubMed ID: 36003918
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies.
    Deitelzweig S; Farmer C; Luo X; Vo L; Li X; Hamilton M; Horblyuk R; Ashaye A
    Curr Med Res Opin; 2017 Sep; 33(9):1583-1594. PubMed ID: 28644048
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis.
    Deitelzweig S; Farmer C; Luo X; Li X; Vo L; Mardekian J; Fahrbach K; Ashaye A
    Curr Med Res Opin; 2018 Mar; 34(3):487-498. PubMed ID: 29188721
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative Risks of Fracture Among Direct Oral Anticoagulants and Warfarin: A Systematic Review and Network Meta-Analysis.
    Tsai SHL; Hu CW; Shao SC; Tischler EH; Obisesan OH; Vervoort D; Chen WC; Hu JR; Kuo LT
    Front Cardiovasc Med; 2022; 9():896952. PubMed ID: 35677694
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association Between Dabigatran vs Warfarin and Risk of Osteoporotic Fractures Among Patients With Nonvalvular Atrial Fibrillation.
    Lau WC; Chan EW; Cheung CL; Sing CW; Man KK; Lip GY; Siu CW; Lam JK; Lee AC; Wong IC
    JAMA; 2017 Mar; 317(11):1151-1158. PubMed ID: 28324091
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
    Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Vo L
    Curr Med Res Opin; 2017 Sep; 33(9):1595-1604. PubMed ID: 28635338
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants.
    Stolk LM; de Vries F; Ebbelaar C; de Boer A; Schalekamp T; Souverein P; Ten Cate-Hoek A; Burden AM
    Br J Clin Pharmacol; 2017 Aug; 83(8):1835-1843. PubMed ID: 28326589
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
    Borne RT; O'Donnell C; Turakhia MP; Varosy PD; Jackevicius CA; Marzec LN; Masoudi FA; Hess PL; Maddox TM; Ho PM
    BMC Cardiovasc Disord; 2017 Sep; 17(1):236. PubMed ID: 28865440
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Left atrial thrombus and dense spontaneous echocardiographic contrast in patients on continuous direct oral anticoagulant therapy undergoing catheter ablation of atrial fibrillation: Comparison of dabigatran, rivaroxaban, and apixaban.
    Wu M; Gabriels J; Khan M; Shaban N; D'Amato S; Liu CF; Markowitz SM; Ip JE; Thomas G; Singh P; Lerman B; Patel A; Cheung JW
    Heart Rhythm; 2018 Apr; 15(4):496-502. PubMed ID: 29605015
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses.
    Briasoulis A; Gao Y; Inampudi C; Alvarez P; Asleh R; Chrischilles E; Leira EC; Vaughan-Sarrazin M
    BMC Cardiovasc Disord; 2020 Feb; 20(1):42. PubMed ID: 32013886
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of the Safety and Effectiveness of Direct-Acting Oral Anticoagulants in Patients with Atrial Fibrillation and Coexisting Valvular Heart Disease.
    Hampton ML; Tellor KB; Armbruster AL; Theodos G; Schwarze MW
    Am J Cardiovasc Drugs; 2020 Dec; 20(6):611-617. PubMed ID: 32043243
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative Effectiveness and Safety of Low-Dose Oral Anticoagulants in Patients With Atrial Fibrillation.
    Perreault S; Dragomir A; Côté R; Lenglet A; de Denus S; Dorais M; White-Guay B; Brophy J; Schnitzer ME; Dubé MP; Tardif JC
    Front Pharmacol; 2021; 12():812018. PubMed ID: 35095525
    [No Abstract]   [Full Text] [Related]  

  • 56. Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function.
    Pham P; Schmidt S; Lesko L; Lip GYH; Brown JD
    JAMA Netw Open; 2020 Apr; 3(4):e203593. PubMed ID: 32329770
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland.
    Mueller T; Alvarez-Madrazo S; Robertson C; Wu O; Bennie M
    Br J Clin Pharmacol; 2019 Feb; 85(2):422-431. PubMed ID: 30423191
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study.
    Abraham NS; Noseworthy PA; Yao X; Sangaralingham LR; Shah ND
    Gastroenterology; 2017 Apr; 152(5):1014-1022.e1. PubMed ID: 28043907
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A rapid evidence assessment of bleed-related healthcare resource utilization in publications reporting the use of direct oral anticoagulants for non-valvular atrial fibrillation.
    Shah BR; Scholtus E; Rolland C; Batscheider A; Katz JN; Nilsson KR
    Curr Med Res Opin; 2019 Jan; 35(1):127-139. PubMed ID: 30380959
    [No Abstract]   [Full Text] [Related]  

  • 60. Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study.
    Durand M; Schnitzer ME; Pang M; Carney G; Eltonsy S; Filion KB; Fisher A; Jun M; Kuo IF; Renoux C; Paterson JM; Quail J; Matteau A;
    CMAJ Open; 2020; 8(4):E877-E886. PubMed ID: 33355273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.